Evidence map›Paper›PMID 35384035›Full record

ArticleJournal of leukocyte biology2022

Cross-reactive cellular, but not humoral, immunity is detected between OC43 and SARS-CoV-2 NPs in people not infected with SARS-CoV-2: Possible role of cT

Álvaro Fernando García-Jiménez, Yaiza Cáceres-Martell, Daniel Fernández-Soto, Pedro Martínez Fleta, José M Casasnovas, Francisco Sánchez-Madrid, José Miguel Rodríguez Frade, Mar Valés-Gómez, Hugh T Reyburn

Open access · bronzeAbstract read
In one paragraph

Article in Journal of leukocyte biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Human coronavirus OC43-elicited CD4Nature communications · 2024
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Álvaro Fernando García-JiménezDepartment of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.
Yaiza Cáceres-MartellDepartment of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.
Daniel Fernández-SotoDepartment of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.
Pedro Martínez FletaImmunology Department, Hospital Universitario La Princesa IIS-IP, Madrid, Spain.
José M CasasnovasDepartment of Macromolecular Structures, National Centre for Biotechnology, CNB-CSIC, CNB, Madrid, Spain.
Francisco Sánchez-MadridImmunology Department, Hospital Universitario La Princesa IIS-IP, Madrid, Spain.
José Miguel Rodríguez FradeDepartment of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.
Mar Valés-GómezDepartment of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.
Hugh T ReyburnDepartment of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.
Centro Nacional de Biotecnología · ESHospital Universitario de La Princesa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple questions about SARS-CoV-2 humoral and cellular immunity remain unanswered. One key question is whether preexisting memory T or B cells, specific for related coronaviruses in SARS-CoV-2-unexposed individuals, can recognize and suppress COVID-19, but this issue remains unclear. Here, we demonstrate that antibody responses to SARS-CoV-2 antigens are restricted to serum samples from COVID-19 convalescent individuals. In contrast, cross-reactive T cell proliferation and IFN-γ production responses were detected in PBMCs of around 30% of donor samples collected prepandemic, although we found that these prepandemic T cell responses only elicited weak cT

Indexed as

Coronavirus OC43, HumanCOVID-19Antibodies, ViralCross ReactionsHumansImmunity, HumoralSARS-CoV-2Antibodies, ViralCOVID-19cross-reactive immunityHCoV-OC43SARS-CoV-2

Identifiers

PMID35384035
PMCPMC9088540
OpenAlexW4226151627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.